American Journal of Ophthalmology
Volume 152, Issue 6 , Pages 1014-1020 , December 2011

Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994–2007

  • Shelley Day

      Affiliations

    • Department of Ophthalmology, Duke Eye Center, Durham, North Carolina
    • ,
  • Kofi Acquah

      Affiliations

    • Department of Economics, Duke University, Durham, North Carolina
    • ,
  • Paul P. Lee

      Affiliations

    • Department of Ophthalmology, Duke Eye Center, Durham, North Carolina
    • ,
  • Prithvi Mruthyunjaya

      Affiliations

    • Department of Ophthalmology, Duke Eye Center, Durham, North Carolina
    • ,
  • Frank A. Sloan

      Affiliations

    • Department of Ophthalmology, Duke Eye Center, Durham, North Carolina
    • Department of Economics, Duke University, Durham, North Carolina
    • Corresponding Author InformationInquiries to Frank A. Sloan, Box 90097, 236 Social Sciences Building, Department of Economics, Duke University, Durham, NC 27708

,Accepted 10 May 2011.

References 

  1. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57–65.e5
  2. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805–2816
  3. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–572
  4. Evans JR, Fletcher AE, Wormald RP. Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community. Ophthalmology. 2004;111(3):513–517
  5. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844–851
  6. Coleman AL, Yu F, Ensrud KE, et al. Impact of age-related macular degeneration on vision-specific quality of life: Follow-up from the 10-year and 15-year visits of the Study of Osteoporotic Fractures. Am J Ophthalmol. 2010;150(5):683–691
  7. Dong LM, Childs AL, Mangione CM, et al. Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. Am J Ophthalmol. 2004;138(1):91–108
  8. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431
  9. Fong DS, Custis P, Howes J, Hsu JW. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study. Ophthalmology. 2010;117(2):298–302
  10. Smiddy WE. Economic implications of current age-related macular degeneration treatments. Ophthalmology. 2009;116(3):481–487
  11. Gower EW, Cassard SD, Bass EB, Schein OD, Bressler NM. A cost-effectiveness analysis of three treatments for age-related macular degeneration. Retina. 2010;30(2):212–221
  12. Brown MM, Brown GC, Brown HC, Peet J. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology. 2008;115(6):1039–1045.e5
  13. Coleman AL, Yu F. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999. Ophthalmology. 2008;115(1):18–25
  14. Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol. 2011;151(5):887–895.e1
  15. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124(12):1754–1760
  16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383
  17. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55
  18. D'Agostino R. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–2281
  19. Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001;54(4):387–398
  20. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26(4):734–753
  21. Ramulu PY, Do DV, Corcoran KJ, Corcoran SL, Robin AL. Use of retinal procedures in medicare beneficiaries from 1997 to 2007. Arch Ophthalmol. 2010;128(10):1335–1340
  22. Sloan FA, Brown DS, Carlisle ES, Picone GA, Lee PP. Monitoring visual status: why patients do or do not comply with practice guidelines. Health Serv Res 004;39(5):1429-1448.
  23. Salm M, Belsky D, Sloan FA. Trends in cost of major eye diseases to Medicare, 1991 to 2000. Am J Ophthalmol. 2006;142(6):976–982
  24. Schmier JK, Covert DW, Lau EC, Robin AL. Trends in annual medicare expenditures for glaucoma surgical procedures from 1997 to 2006. Arch Ophthalmol. 2009;127(7):900–905
  25. Klein R, Cruickshanks KJ, Nash SD, et al. The prevalence of age-related macular degeneration and associated risk factors. Arch Ophthalmol. 2010;128(6):750–758
  26. CATT Research GroupMartin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–1908

PII: S0002-9394(11)00410-7

doi: 10.1016/j.ajo.2011.05.008

American Journal of Ophthalmology
Volume 152, Issue 6 , Pages 1014-1020 , December 2011

Article Tools